• Helen Saunders, Joan C Schertz, Clara Hecker, Barbara Lang, and Pablo Arriagada.
• Merck Serono S.A., Geneva, Switzerland. helen.saunders@merckgroup.com
• Expert Opin Drug Deliv. 2012 Aug 1; 9 (8): 893-900.

ObjectivesThe first prefilled pen for administration of recombinant human chorionic gonadotropin (r-hCG) has been developed. Usability testing was undertaken to evaluate the risk of dosing errors versus the existing r-hCG prefilled syringe, and assess function and handling of the pen.MethodsInfertile women who were trying to conceive, and specialist nurses, were recruited in Germany. Usability goals were defined and categorized as critical or functional operational goals. Individual, non-interventional, standardized, usability tests (including ease-of-use assessment) were performed with patients and nurses. Cumulative test scores for critical operations were compared. Non-standardized qualitative analyses of nurse-patient training sessions were performed.ResultsThe cumulative test score for the r-hCG prefilled pen was better than that of the existing prefilled syringe, so it was concluded that the overall risk of dosing errors was not higher with the pen. The ease of use of the pen was rated favorably by patients and nurses. Both user groups were confident that they could inject the correct dose using the pen.ConclusionsThe overall risk of dosing errors was not higher with the r-hCG prefilled pen than the existing prefilled syringe. The ease-of-use of the r-hCG prefilled pen was rated favorably by patients and nurses.

28 keywords...

hide…